Breaking News Instant updates and real-time market news.

EARS

Auris Medical

$1.62

-0.02 (-1.22%)

, YHOO

Yahoo

$43.92

0.7 (1.62%)

17:34
10/10/16
10/10
17:34
10/10/16
17:34

On The Fly: After Hours Movers

HIGHER: Auris Medical (EARS), up 2.5% after it scheduled a conference call for October 11 to provide an update on the Keyzilen development program... Yahoo (YHOO), up 1% after Verizon (VZ) chief executive officer Lowell McAdam said that the report that it was seeking a $1B discount to its deal to acquire Yahoo was "total speculation"... Coca-Cola (KO), up 0.2% after it exercised its option to buy AB InBev's (BUD) stake in Coca-Cola Beverages Africa following the closing of its merger with SABMiller (SBMRY). LOWER: Illumina (ILMN), down 24.1% after cutting its third quarter revenue view... Pacific Biosciences (PACB), down 5.6% after gene-sequencing rival Illumina cut its Q3 revenue guidance due to larger than anticipated year-over-year decline in high throughput sequencing instruments... Heritage Insurance (HRTG), down 1.8% after it said it sees losses from Hurricane Matthew amounting to under $100M.

EARS

Auris Medical

$1.62

-0.02 (-1.22%)

YHOO

Yahoo

$43.92

0.7 (1.62%)

VZ

Verizon

$50.19

0.27 (0.54%)

KO

Coca-Cola

BUD

AB InBev

$127.49

0.24 (0.19%)

SBMRY

SABMiller

$55.30

-0.38 (-0.68%)

ILMN

Illumina

$184.85

0.36 (0.20%)

PACB

Pacific Biosciences

$9.05

0.18 (2.03%)

HRTG

Heritage Insurance

$12.73

-0.47 (-3.56%)

  • 10

    Oct

  • 11

    Oct

  • 20

    Oct

  • 23

    Oct

  • 26

    Oct

  • 01

    Nov

  • 07

    Nov

EARS Auris Medical
$1.62

-0.02 (-1.22%)

08/19/16
NEED
08/19/16
NO CHANGE
Target $5
NEED
Buy
Auris Medical price target lowered to $5 from $11 at Needham
Needham analyst Serge Belanger lowered his price target for Auris Medical to $5 from $11 after the company announced that TACTT2, the first of two Phase 3 trials evaluating Keyzilen for the treatment of tinnitus, did not meet either of its co-primary endpoints. The analyst reiterates a Buy rating on the shares.
05/24/16
JMPS
05/24/16
NO CHANGE
JMPS
Auris Medical studies could result in FDA approval, says JMP Securities
JMP Securities believes that there is a reasonably good chance that data due in 2H16 will show that Auris' AM-101 is the first drug that successfully treats tinnitus. The firm says that if this proves to be the case, the FDA should approve the drug based on the data. It reiterates an $8 price target and Outperform rating on the shares.
08/18/16
JMPS
08/18/16
DOWNGRADE
JMPS
Market Perform
Auris Medical downgraded to Market Perform from Outperform at JMP Securities
YHOO Yahoo
$43.92

0.7 (1.62%)

09/16/16
OPCO
09/16/16
NO CHANGE
Target $55
OPCO
Outperform
Yahoo price target raised to $55 from $48 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Yahoo (YHOO) to $55 from $48, citing the positive move in Alibaba's (BABA) share price and the $4.1B taxable basis of Yahoo's core, disclosed in a proxy statement. The analyst reiterates an Outperform rating on Yahoo's shares.
09/28/16
SBSH
09/28/16
NO CHANGE
SBSH
Buy
Citi hopes Disney does not acquire Twitter
Citi analyst Jason Bazinet lays out four reasons for why he doesn't like Disney (DIS) pursuing an acquisition of Twitter (TWTR). Going back 15 years, the analyst can't think of a single web-based property that was successfully acquired by a traditional media firm. Two, he calls Twitter trends "troubling." Three, Bazinet estimates a cash offer would lower Disney's stock by $5 per share while an equity offer would drop its stock by $9. Four, the analyst feels it is unclear how Disney's content will help Twitter. Bazinet thinks both Yahoo (YHOO) and Twitter lost "significant money" when they streamed NFL content over the web. The analyst hopes Twitter is acquired by somebody other than Disney. He keeps a Buy rating on Disney shares. Both Loop Capital and Mizuho this morning downgraded Twitter to sell ratings.
09/23/16
BOFA
09/23/16
NO CHANGE
Target $55
BOFA
Buy
BofA thinks Verizon deal stays on track despite Yahoo data breach
Bank of America Merrill Lynch analyst Justin Post said that Yahoo's (YHOO) disclosure of the massive data breach impacting over 500M of its users is clearly a negative for the company that could result in email account closures, but he does not anticipate a major impact on Yahoo's business related to this breach, citing as evidence the fact that he is not aware of any significant business impairment or financial liability related to security breaches at LinkedIn (LNKD) in 2012 and at eBay (EBAY) in 2014. Post adds that the Target (TGT) data breach, which did include credit card info, is not directly comparable to Yahoo's breach. For Verizon (VZ) to back out of its acquisition agreement, Post thinks the company would need to assume Yahoo acted in bad faith during negotiations and that the Yahoo asset is impaired or comes with significant liability, neither of which he sees as being the case. The analyst keeps a Buy rating on Yahoo and bumped his target on the shares to $55 from $53, citing an increased price target on Alibaba (BABA) that a peer at the firm recently set.
09/23/16
RHCO
09/23/16
NO CHANGE
RHCO
Yahoo hack is probably not a material adverse change, says SunTrust
After Yahoo (YHOO) reported that over 500M of its accounts had been hacked, SunTrust analyst Robert Peck thinks that the news is probably not a material adverse change, or MAC, that would jeopardize the company's acquisition by Verizon (VZ). He notes that the sales contract says that a MAC will not be triggered by "any failure by Yahoo to meet its internal or published projections, budgets, plans, or forecasts of its revenues, earnings, or other financial performance or results of operations." The analyst says that the hack "may be manageable," since a majority of the victims could be e-mail users who are sticky. He keeps a Neutral rating on Yahoo.
VZ Verizon
$50.19

0.27 (0.54%)

09/06/16
RHCO
09/06/16
NO CHANGE
Target $18
RHCO
Neutral
SunTrust sees 'limited' list of Twitter suitors, says activist action unlikely
SunTrust analyst Robert Peck reiterated his belief that Twitter (TWTR) is unlikely to sell itself in 2016 in a new note to investors, but noted that investors have asked him who would be interested if Twitter were open to a sale. While giving his opinion on potential acquirers - which he sees possibly including Google (GOOG), Facebook (FB), Apple (AAPL), Amazon (AMZN), Microsoft (MSFT), AT&T (T), Verizon (VZ), Disney (DIS), Fox (FOXA), and Alibaba (BABA) - Peck said the company's high price and "unique" asset limit the potential buyers and gave his view that a PE buyer is highly unlikely given the company's lack of free cash flow. Additionally, Peck thinks activist action at Twitter seems "extremely unlikely" despite "unsubstantiated investor conjecture" and media reports. The analyst keeps Neutral rating and $18 price target on Twitter shares.
09/19/16
WELS
09/19/16
NO CHANGE
WELS
Concerns about Frontier Communications leverage overdone, says Wells Fargo
Wells Fargo says that some investors have expressed concern about Frontier's leverage ratio. Specifically, the firm says there are some worries that if Frontier has difficulty integrating the Verizon (VZ) assets it purchased, it may trigger bank covenants. However, Wells says that Frontier's synergy realization and subscription outlook have improved since Q2. Wells adds that the company's dividend is "very secure neat-term," and it keeps an Outperform rating on the shares.
KO Coca-Cola

09/29/16
STFL
09/29/16
DOWNGRADE
STFL
Hold
Coca-Cola downgraded to Hold from Buy at Stifel
09/29/16
STFL
09/29/16
DOWNGRADE
STFL
Hold
Coca-Cola downgraded following Pepsi results at Stifel
As noted earlier, Stifel analyst Mark Swartzberg downgraded Coca-Cola (KO) to Hold from Buy. The analyst downgraded the stock after Pepsi (PEP) reported better than expected Q3 results. The analyst says that Coca-Cola's and Pepsi's organic EPS growth appears to be similar, but he believes that Pepsi is less vulnerable to foreign exchange fluctuations. Additionally, he believes that Coca Cola European Bottlers (CCE) is a better investment than Coca-Cola because of the large amount of revenue synergies which that Coca Cola European Bottlers has identified.
09/29/16
09/29/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Coca-Cola (KO) downgraded to Hold from Buy at Stifel with analyst Mark Swartzberg saying that Coca-Cola's and Pepsi's organic EPS growth appears to be similar, but he believes that Pepsi is less vulnerable to foreign exchange fluctuations. 2. Fitbit (FIT) downgraded to Underweight from Sector Weight at Pacific Crest analyst Brad Erickson citing his channel checks which indicated that Charge 2, the company's flagship holiday product, is off to a slow start. 3. Discovery (DISCA) downgraded to Market Perform from Outperform at Barrington with analyst James Goss saying that Brexit and sports costs are dragging on its international results and foreign exchange tailwinds are moderating in many geographies. 4. Sonus (SONS) downgraded to Underperform from Market Perform at Cowen with analyst Paul Silverstein saying the firm's industry checks uncovered operational challenges and ongoing employee and executive churn. 5. Alcobra (ADHD) downgraded to Hold from Buy at Cantor and to Perform from Outperform at Oppenheimer. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/29/16
HSBC
09/29/16
NO CHANGE
HSBC
Buy
AB InBev's goal may be to acquire Coca-Cola, says HSBC
HSBC analyst Anthony Bucalo says SABMiller's (SBMRY) merger with AB InBev (BUD), which its shareholders just approved, will impact "nearly every major company across global beverages," especially Heinenken (HINKY). The combined company "represents a strong vehicle for another transaction" if InBev management chooses to do so, Bucalo tells investors in a research note dated yesterday. The analyst believes AB InBev's ultimate goal is the possible acquisition of The Coca-Cola Company (KO). The entire Coca-Cola bottling system, especially for Mexican giant FEMSA (FMX), is impacted by SABMiller joining with AB InBev, Bucalo contends.
BUD AB InBev
$127.49

0.24 (0.19%)

10/05/16
MSCO
10/05/16
INITIATION
MSCO
Overweight
AB InBev coverage resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Oliver Nicolai resumed coverage on AB InBev with an Overweight saying the SAB acquisition significantly increases volume and sales growth.
10/10/16
GSCO
10/10/16
INITIATION
GSCO
Buy
AB InBev reinstated with a Buy at Goldman
10/10/16
10/10/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Sell at Deutsche Bank. 2. Noble Midstream (NBLX) initiated with an Overweight at Barclays, a Hold at Deutsche Bank, an Overweight at JPMorgan, an Outperform at Baird, a Buy at Mizuho, a Buy at Citi, and an Overweight at MUFG. 3. AB InBev (BUD) reinstated with a Buy at Goldman. 4. First Solar (FSLR) initiated with a Neutral at Piper Jaffray. First Solar (FSLR) initiated with a Neutral at Piper Jaffray. 5. Molson Coors (TAP) reinstated with a Buy at Goldman and resumed with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/05/16
10/05/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Netflix (NFLX) initiated with a Buy at Loop Capital. 2. AB InBev (BUD) coverage resumed with an Overweight at Morgan Stanley. 3. Flowers Foods (FLO) initiated with a Neutral at DA Davidson. 4. Blue Buffalo Pet Products (BUFF) initiated with a Buy at DA Davidson. 5. 58.com (WUBA) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SBMRY SABMiller
$55.30

-0.38 (-0.68%)

07/19/16
STFL
07/19/16
NO CHANGE
STFL
SABMiller deal could be blocked, terms may be sweetened says Stifel
Stifel believes that a minority SABMiller (SBMRY) shareholders could "effectively block" the company's proposed acquisition by AB InBev (BUD). The firm thinks that the deal's small premium and "the illiquidity" of AB's stock that would be transferred in the alternative, partial stock offering could motivate SABMiller's shareholders to block the deal. The firm thinks that AB InBev could sweeten the terms of the deal.
07/29/16
SBSH
07/29/16
UPGRADE
Target $115
SBSH
Buy
Molson Coors upgraded to Buy from Neutral at Citi
Citi analyst Wendy Nicholson upgraded Molson Coors (TAP) to Buy citing the recent pullback in the shares. The analyst is optimistic that both the AB InBev (BUD)/SABMiller (SBMRY) and Molson Coors/MillerCoors transactions will close in early Fall 2016. Nicholson raised her price target for the shares to $115 from $101.
03/22/16
03/22/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. EP Energy (EPE) downgraded to Underperform and Underweight at BofA/Merrill and Capital One, respectively, with analysts saying EP Energy's planned sale of Haynesville for $420mm is not a surprise and balance sheet headwinds remain. BofA/Merrill continues to see leverage as a headwind and does not see how the company can live within its cash flow while production declines in 2016. 2. Amazon.com (AMZN) downgraded to Outperform at Raymond James by analyst Aaron Kessler, who expects Amazon's pace of margin expansion to slow and he sees increased competition to its Web Services unit from Google's (GOOG, GOOGL) Cloud Platform. 3. Copa Holdings (CPA) downgraded to Sell at Evercore ISI by analyst Duane Pfennigwerth, who cited recent shares strength. 4. Infinity Pharmaceuticals (INFI) downgraded to Underperform from Neutral at Wedbush. 5. SABMiller (SBMRY) downgraded to Underperform at CLSA. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ILMN Illumina
$184.85

0.36 (0.20%)

09/12/16
SBSH
09/12/16
NO CHANGE
Target $190
SBSH
Buy
Illumina price target raised to $190 from $175 at Citi
Citi analyst Daniel Arias raised his price target for Illumina to $190 after traveling with the company's CFO Marc Stapley and investor relations head Rebecca Chambers. The analyst believes the business "can hold its own" in the second half of 2016 and that shares can move higher in 2017. He keeps a Buy rating on Illumina.
08/22/16
KING
08/22/16
DOWNGRADE
KING
Neutral
Illumina downgraded to Neutral from Buy at CL King
CL King analyst David Westenberg downgraded Illumina to Neutral given the recent run-up in the shares and lack of near-term visible catalysts.
08/18/16
CANT
08/18/16
NO CHANGE
Target $165
CANT
Speculative Buy
Thermo Fisher unlikely to acquire Illumina, says Cantor
Cantor Fitzgerald analyst Bryan Brokmeier believes it is unlikely that Thermo Fisher (TMO) will attempt to acquire Illumina (ILMN). Even if Thermo were to attempt a deal, the merger would be unlikely to close, Brokmeier tells investors in an intraday research note. If Illumina is a willing seller, however, Roche (RHHBY) may reconsider a bid, the analyst contends. He recommends investors stay on the sidelines with respect to Illumina shares. Brokmeier has a Hold rating on the name with a $165 price target. The analyst continues to believe Roche is the most likely acquirer of Pacific Biosciences (PACB).
08/18/16
WELS
08/18/16
NO CHANGE
WELS
Wells Fargo says Thermo Fisher buying Illumina 'makes no sense'
Wells Fargo analyst Tim Evans believes speculation of Thermo Fisher (TMO) acquiring Illumina "makes no sense." The analyst estimates the deal would be about 14% dilutive to Thermo in year one and "would struggle to be neutral" to earnings by year three. Further, the deal would run into "significant regulatory hurdles" since that Illumina holds a near monopoly in high-throughput sequencing, Evans tell investors note. Shares of Illumina are off their highs but remain up 3% after StreetInsider stoked renewed takeout speculation by citing a source saying Thermo may bid $30B for the company.
PACB Pacific Biosciences
$9.05

0.18 (2.03%)

08/04/16
08/04/16
NO CHANGE

On The Fly: After Hours Movers
UP AFTER EARNINGS: Pacific Biosciences (PACB), up 17%... MasTec (MTZ), up 9.6%... Aratana Therapeutics (PETX), up 9.2%... Lion's Gate (LGF), up 6.4%... Priceline (PCLN), up 5.7%... Ubiquiti (UBNT), up 5.5%... MercadoLibre (MELI), up 4.1%... Organovo (ONVO), up 3.9%... Kraft Heinz (KHC), up 3.3%... EOG Resources (EOG), up 2.8%... Monster Beverage (MNST), up 1.2%... TASER (TASR), up 1.2%... Take-Two (TTWO), up 0.9%... Activision Blizzard (ATVI), up 1%... BioMarin (BMRN), up 0.4%. ALSO HIGHER: Egalet (EGLT), up 31.2% after the company announced that an FDA advisory committee recommended approval of its ARYMO ER drug... Rackspace (RAX), up 17.6% after the Wall Street Journal reported that the company was near a takeover deal with a private equity buyer... Osiris (OSIR), up 8.5% after it said that the manuscript from its prospective trial using Grafix was published. DOWN AFTER EARNINGS: Hortonworks (HDP), down 26.2%... PDL BioPharma (PDLI), down 17.5%... FireEye (FEYE), down 15.8%... Sierra Wireless (SWIR), down 15.6%... Aquinox (AQXP), down 14.7%... Zynga (ZNGA), down 9.4%... Universal Display (OLED), down 8.2%... Weight Watchers (WTW), down 7.6%... Zillow Group (Z, ZG), down 5.5%... Arista Networks (ANET), down 4.5%... Noodles & Company (NDLS), down 4.3%... Merrimack (MACK), down 1.7%... Bankrate (RATE), down 1.7%.
04/22/16
CANT
04/22/16
NO CHANGE
CANT
Pacific Biosciences should be bought after strong Q1 results, says Cantor
Cantor recommends that investors buy the shares of Pacific Biosciences after the company reported stronger than expected Q1 results. The firm thinks that the company's increased guidance may be conservative, and it believes that the company could have at least 30 bookings in Q2. Cantor keeps an $18 price target and Buy rating on the shares.
04/18/16
PIPR
04/18/16
NO CHANGE
Target $11
PIPR
Neutral
Pacific Biosciences estimates lowered on Sequel checks at Piper Jaffray
Piper Jaffray analyst William Quirk lowered his Q1 estimates for Pacific Biosciences after his initial round of Sequel channel checks found six placements during the quarter compared to the 17 he modeled. Assuming Roche placed five systems, the Q1 total would come to 11, Quirk tells investors in a research note. The analyst keeps a Neutral rating on the shares with an $11 price target.
HRTG Heritage Insurance
$12.73

-0.47 (-3.56%)

09/23/16
SDLR
09/23/16
UPGRADE
Target $16
SDLR
Buy
Heritage Insurance upgraded to Buy from Hold at Sandler O'Neill
Sandler O'Neill analyst John Barnidge upgraded Heritage Insurance to Buy with the majority of hurricane season now passed. The shares at current levels are not appropriately valuing the company's "solidly mid-teens return-on-equity profile," Barnidge tells investors in a research note. He raised his price target for Heritage to $16 from $15.
03/04/16
JMPS
03/04/16
NO CHANGE
JMPS
Heritage Insurance weakness overdone, says JMP Securities
After Heritage fell 10% following its better than expected Q4 results, JMP Securities believes that the company's growth outlook is positive, while its EPS and book value should both rise significantly going forward. JMP says that the company's acquisition of wind-only insurer Zephyr will be accretive, and JMP notes that the company has expanded into several new markets. JMP keeps a $25 price target and Outperform rating on the shares.
03/04/16
SDLR
03/04/16
DOWNGRADE
Target $19
SDLR
Hold
Heritage Insurance downgraded to Hold from Buy at Sandler O'Neill
Sandler O'Neill analyst John Barnidge downgraded Heritage Insurance to Hold with a $19 price target. The company's Q1 is expected to be its highest loss ratio while property pricing has been declining amid the lack of hurricane activity, Barnidge tells investors in a research note.
10/20/15
10/20/15
UPGRADE

On The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Aimco (AIV) upgraded to Strong Buy at Raymond James... Boston Beer (SAM) upgraded to Neutral from Sell at Goldman... CNOOC (CEO) upgraded to Overweight from Equal Weight at Barclays... Deutsche Telekom (DTEGY) upgraded to Conviction Buy from Neutral at Goldman... Etsy (ETSY) upgraded to Neutral from Underperform at Wedbush... Genuine Parts (GPC) upgraded to Buy from Hold at Gabelli... GlaxoSmithKline (GSK) upgraded to Neutral from Underperform at Credit Suisse... HCI Group (HCI) upgraded to Outperform from Market Perform at JMP Securities... Heritage Insurance (HRTG) upgraded to Outperform from Market Perform at JMP Securities... LVMH (LVMUY) upgraded to Buy from Neutral at Nomura... Mid-America Apartment (MAA) upgraded to Outperform at Raymond James... Mizuho Financial Group (MFG) upgraded to Overweight from Equal Weight at Barclays... Och-Ziff Capital (OZM) upgraded to Buy from Neutral at Compass Point... PetroChina (PTR) upgraded to Overweight from Equal Weight at Barclays... Pfizer (PFE) upgraded to Outperform from Market Perform at Cowen... Randgold (GOLD) upgraded to Buy from Hold at Deutsche Bank... Rice Energy (RICE) upgraded to Outperform from Sector Perform at RBC Capital... Rogers Communications (RCI) upgraded to Outperform from Neutral at Macquarie... Select Medical (SEM) upgraded on valuation at JMP Securities... Shaw Communications (SJR) upgraded to Outperform from Neutral at Macquarie... Synchrony (SYF) upgraded to Buy from Neutral at Nomura... Tallgrass Energy GP (TEGP) upgraded to Outperform from Neutral at Baird... Targa Resources Partners (NGLS) upgraded to Outperform from Neutral at Baird... The Fresh Market (TFM) upgraded to Neutral from Underperform at Credit Suisse... Weight Watchers (WTW) upgraded to Equal Weight from Underweight at Barclays.

TODAY'S FREE FLY STORIES

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

09:15
12/03/16
12/03
09:15
12/03/16
09:15
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

04:55
12/03/16
12/03
04:55
12/03/16
04:55
General news
Breaking General news story  »

New York Federal Reserve…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

, ESALY

Eisai

$57.91

0.59 (1.03%)

04:55
12/03/16
12/03
04:55
12/03/16
04:55
Conference/Events
American Epilepsy Society to hold annual meeting »

70th Annual Meeting of…

BMRN

BioMarin

$82.21

-1.12 (-1.34%)

ESALY

Eisai

$57.91

0.59 (1.03%)

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

IART

Integra LifeSciences

$75.78

-1.07 (-1.39%)

MDT

Medtronic

$72.01

0.13 (0.18%)

MNK

Mallinckrodt

$53.61

0.51 (0.96%)

NVTA

Invitae

$6.95

0.16 (2.36%)

SAGE

SAGE Therapeutics

$49.02

-0.23 (-0.47%)

WTKWY

Wolters Kluwer

$34.08

-0.39 (-1.13%)

ZGNX

Zogenix

$13.05

0.35 (2.76%)

ZYNE

Zynerba

$13.64

0.83 (6.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 05

    Dec

  • 06

    Dec

  • 07

    Dec

  • 12

    Dec

  • 14

    Dec

  • 28

    Jan

  • 27

    Apr

WMT

Wal-Mart

$70.88

0.21 (0.30%)

18:17
12/02/16
12/02
18:17
12/02/16
18:17
Periodicals
Wal-Mart to pay $7.5M to settle same-sex spouse benefit case, Reuters reports »

Wal-Mart said it would…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

18:14
12/02/16
12/02
18:14
12/02/16
18:14
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

, ALIOF

Actelion

$206.01

15.21 (7.97%)

18:11
12/02/16
12/02
18:11
12/02/16
18:11
Periodicals
Johnson & Johnson said to raise offer for Actelion above $250, Bloomberg says »

Johnson &…

JNJ

Johnson & Johnson

$111.96

0.58 (0.52%)

ALIOF

Actelion

$206.01

15.21 (7.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$79.10

0.3 (0.38%)

18:00
12/02/16
12/02
18:00
12/02/16
18:00
Hot Stocks
Celanese to raise list, off-list selling prices for paraformaldehyde »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, GMED

Globus Medical

$21.89

0.12 (0.55%)

17:56
12/02/16
12/02
17:56
12/02/16
17:56
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: HomeStreet…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

GMED

Globus Medical

$21.89

0.12 (0.55%)

BGS

B&G Foods

$42.50

0.2 (0.47%)

ZEN

Zendesk

$21.17

0.34 (1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

  • 09

    Jan

ZEN

Zendesk

$21.17

0.34 (1.63%)

17:53
12/02/16
12/02
17:53
12/02/16
17:53
Hot Stocks
Zendesk says SVPs Amanda Kleha and Marcus Bragg to resign »

On November 29, Amanda…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Dec

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:42
12/02/16
12/02
17:42
12/02/16
17:42
Periodicals
President Obama blocks China's Fujian from acquiring Aixtron, CNBC reports »

President Barack Obama…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CX

CEMEX

$7.83

0.09 (1.16%)

17:31
12/02/16
12/02
17:31
12/02/16
17:31
Hot Stocks
CEMEX to divest ready-mix concrete pumping assets in Mexico »

CEMEX announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRNE

Sorrento Therapeutics

$5.15

-0.1 (-1.90%)

17:30
12/02/16
12/02
17:30
12/02/16
17:30
Syndicate
Breaking Syndicate news story on Sorrento Therapeutics »

Sorrento files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

MBRX

Moleculin Biotech

$2.63

-0.14 (-5.05%)

17:29
12/02/16
12/02
17:29
12/02/16
17:29
Syndicate
Breaking Syndicate news story on Moleculin Biotech »

Moleculin Biotech files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NEOG

Neogen

$61.59

-1.46 (-2.32%)

17:28
12/02/16
12/02
17:28
12/02/16
17:28
Hot Stocks
Neogen acquires U.K.-based Quat-Chem, terms undisclosed »

Neogen announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RRC

Range Resources

$36.36

-0.23 (-0.63%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Hot Stocks
Breaking Hot Stocks news story on Range Resources »

SailingStone Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$103.74

-1.01 (-0.96%)

17:25
12/02/16
12/02
17:25
12/02/16
17:25
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

, UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

17:22
12/02/16
12/02
17:22
12/02/16
17:22
Hot Stocks
Breaking Hot Stocks news story on HomeStreet, UMB Financial »

HomeStreet to replace UMB…

HMST

HomeStreet

$29.35

-0.2 (-0.68%)

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

, IM

Ingram Micro

$38.88

1.31 (3.49%)

17:21
12/02/16
12/02
17:21
12/02/16
17:21
Hot Stocks
UMB Financial to replace Ingram Micro in S&P 400 as of 12/6 close »

Tianjin Tianhai…

UMBF

UMB Financial

$77.00

-0.43 (-0.56%)

IM

Ingram Micro

$38.88

1.31 (3.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GMED

Globus Medical

$21.89

0.12 (0.55%)

, TLN

Talen Energy

17:20
12/02/16
12/02
17:20
12/02/16
17:20
Hot Stocks
Globus Medical to replace Talen Energy in S&P 400 as of 12/6 close »

Riverstone Holdings is…

GMED

Globus Medical

$21.89

0.12 (0.55%)

TLN

Talen Energy

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AIXG

Aixtron

$3.97

-0.05 (-1.24%)

17:16
12/02/16
12/02
17:16
12/02/16
17:16
Periodicals
President Obama blocks China's takeover of Aixtron, CNBC reports »

Says the transaction…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DB

Deutsche Bank

$15.74

-0.32 (-1.99%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Periodicals
Deutsche Bank to pay $60M settlement over gold price-fixing case, Reuters says »

Deutsche Bank will pay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

ALB

Albemarle

$84.86

-0.79 (-0.92%)

17:07
12/02/16
12/02
17:07
12/02/16
17:07
Hot Stocks
Albemarle to increase prices for select brominated products »

Albemarle announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Mar

FOR

Forestar Group

$13.40

0.2 (1.52%)

17:06
12/02/16
12/02
17:06
12/02/16
17:06
Hot Stocks
Breaking Hot Stocks news story on Forestar Group »

Carlson Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.